Company profile
Provectus Biopharmaceuticals, Inc.
OTC: PVCT · Healthcare · Biotechnology
#965 of 1,422 Healthcare companies by revenuebottom-quartile growth
EA Score
35DFH 18DQ 57GM 35SS 54
v0.1 · 65/100 weight · provisional
↑ listing tenure, disclosure history · ↓ Altman-Z, return on assets
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$5.4M
Employees
6
as of 2026-08-20
Market cap
$24.4M
as of 2026-08-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$336.1k$336.1k2025
Net income-$5.4M-$5.4M2025
Operating income-$5.3M-$5.3M2025
Total assets$697.5k$697.5k2025
Liabilities$7.0M$7.0M2025
Equity-$6.3M-$6.3M2025
Revenue trend
FY2012 – FY2025 · USD
FY12
FY13
FY14
FY15
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Provectus Biopharmaceuticals, Inc.’s revenue?
Provectus Biopharmaceuticals, Inc. booked $336.1k in FY2025 revenue, contracting 46% year over year — slower than 80% of Healthcare companies we track, at a -1615.8% net margin.
Peers · Healthcare
Core One Labs Inc.——Pulse Biosciences, Inc.43DMedX Health Corp29DGold River Productions, Inc.——Allarity Therapeutics, Inc.25DVyome Holdings, Inc.33DNeighbors
Knox →Key facts
CEOEdward V. Pershing
SectorHealthcare
IndustryBiotechnology
HeadquartersKnoxville, TN
ExchangeOTC: PVCT
Employees6
IPO date1997-01-15
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.